Speciogynine: Serotonin Pharmacology, Human Exposure & Safety Gaps

What is speciogynine?

Speciogynine is a naturally occurring kratom indole alkaloid and a stereochemical relative of mitragynine. Its name identifies a molecule, not a kratom strain, a product specification, or an established treatment. Its receptor findings should not be replaced with findings for mitragynine or 7-OH. Alkaloid study

Safety boundary: There is no established safe consumer dose of isolated speciogynine in this review. This page provides no medication-substitution or combination advice. Read the medical disclaimer.

Human evidence

Speciogynine was measured in a small healthy-adult study after mixed kratom tea. This establishes exposure in that product setting, rather than a clinical benefit attributable to isolated speciogynine. Multiple alkaloids were present, and the design did not separate their clinical contributions. Human PK study

No controlled isolated-speciogynine efficacy trial was identified in the primary sources reviewed. In particular, the literature cited here does not establish treatment of depression, anxiety, pain, or opioid withdrawal. Measuring a molecule in plasma is useful evidence, but it answers a different question from whether that molecule improves a patient outcome.

Preclinical evidence

A 2021 study investigated serotonin binding and functional responses, alongside rat behavioral experiments. Speciogynine-associated antinociception and lower-lip retraction were sensitive to a selective 5-HT1A antagonist. These are experimental endpoints, not human mood scales or controlled clinical pain outcomes. Serotonin study

The rat experiments also do not tell us which component explains a person's response to a retail kratom product. Translating them requires exposure measurements, replication, and direct clinical testing. Describing a compound as serotonergic should therefore preserve the experimental context instead of implying that it functions like a tested psychiatric medicine.

Pharmacology and receptors

Speciogynine bound 5-HT1A and 5-HT2B receptors in the serotonin study, but binding did not mean activation at both targets. The tested parent compound and its 9-O-desmethyl metabolite had different functional behavior; neither activated 5-HT2B in the reported assays. That negative result does not establish long-term cardiac safety. Functional experiments

Opioid activity also needs careful wording. The 2016 assays found no measurable opioid agonism for speciogynine; the 2026 human-receptor cAMP assay reported weak-potency, partial MOR agonism. Preserve that disagreement without transferring 7-OH's profile to speciogynine. “Interacts with an opioid receptor” is not interchangeable with “produces a clinically demonstrated opioid effect.” 2016 · 2026

Metabolism and pharmacokinetics

The serotonin experiments support a metabolite-mediated hypothesis involving 9-O-desmethylspeciogynine. This is a mechanistic explanation for experimental findings, not a quantified demonstration of that pathway's clinical importance. Metabolite assays

Human parent-alkaloid measurements after tea provide a separate observation. The reviewed evidence does not establish isolated-product oral bioavailability, repeated-exposure accumulation, or a reliable consumer onset and duration. A metabolite's receptor activity cannot supply those missing PK parameters. Likewise, an exposure measurement after a mixture cannot resolve how an isolated preparation would behave.

Safety

Long-term, reproductive, developmental, and organ-specific safety of isolated speciogynine remains unestablished here. The absence of 5-HT2B activation in one study should not be advertised as proof of cardiac safety. FDA's broader kratom safety warnings apply to product-level decisions, without proving speciogynine individually caused the reported harms. FDA

Dependence and withdrawal

These sources do not quantify human dependence or withdrawal from isolated speciogynine. Kratom-mixture reports cannot assign that risk to one constituent. A weak or absent agonist response in a receptor assay does not demonstrate absence of dependence across repeated human exposures. This gap should remain explicit rather than being converted into a “non-addictive” marketing claim.

Interactions

Serotonin-receptor activity raises questions about co-exposure to serotonergic medicines, but the cited experiments do not establish a speciogynine-specific clinical interaction or diagnose serotonin syndrome. Mechanistic plausibility, a documented clinical interaction, and an absence of studies are distinct evidence categories. No safe combination or medication-changing instruction follows from these findings.

Regulatory status — September 30, 2026

FDA has not approved kratom for medical use; these studies provide no approved therapeutic indication for speciogynine. This page does not establish a comprehensive legal classification for the isolated compound. Do not apply the status of pseudoindoxyl or concentrated 7-OH to it solely because they share a botanical association. FDA

Evidence gaps

The missing steps are isolated-compound human trials, metabolite exposure measurements, repeated-use safety, and clinical interaction studies. The current answer is a preclinical serotonin-pharmacology signal with limited mixture-derived human exposure data, not an established mood or withdrawal therapy.

Related compounds

• Mitragynine: main alkaloid and human-evidence anchor.
• Speciociliatine and mitraciliatine: distinct relatives with different receptor findings.
• 7-Hydroxymitragynine and mitragynine pseudoindoxyl: opioid-active derivatives with separate safety evidence.
• 3-Dehydromitragynine: oxidative metabolite with a preclinical toxicity signal.

Use the substance-use evidence hub for broader clinical context. Primary references and identifiers are listed below.